$7.64 Million in Sales Expected for STRATA Skin Sciences Inc (SSKN) This Quarter

Brokerages forecast that STRATA Skin Sciences Inc (NASDAQ:SSKN) will report $7.64 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for STRATA Skin Sciences’ earnings, with the highest sales estimate coming in at $7.67 million and the lowest estimate coming in at $7.60 million. STRATA Skin Sciences reported sales of $7.48 million in the same quarter last year, which would suggest a positive year over year growth rate of 2.1%. The business is expected to issue its next quarterly earnings report before the market opens on Tuesday, November 13th.

According to Zacks, analysts expect that STRATA Skin Sciences will report full-year sales of $29.70 million for the current year, with estimates ranging from $29.40 million to $30.00 million. For the next financial year, analysts anticipate that the firm will post sales of $34.15 million, with estimates ranging from $33.80 million to $34.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for STRATA Skin Sciences.

STRATA Skin Sciences (NASDAQ:SSKN) last released its earnings results on Monday, August 13th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $7.53 million for the quarter, compared to analyst estimates of $6.84 million. STRATA Skin Sciences had a negative return on equity of 27.01% and a negative net margin of 63.07%.

SSKN has been the topic of a number of research analyst reports. Dawson James initiated coverage on STRATA Skin Sciences in a report on Tuesday, September 4th. They issued a “buy” rating on the stock. HC Wainwright set a $3.00 target price on STRATA Skin Sciences and gave the company a “buy” rating in a report on Tuesday, August 14th. Finally, Zacks Investment Research lowered STRATA Skin Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 1st.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SSKN. Nantahala Capital Management LLC acquired a new stake in STRATA Skin Sciences in the 2nd quarter valued at approximately $4,261,000. Menora Mivtachim Holdings LTD. acquired a new stake in shares of STRATA Skin Sciences during the 2nd quarter worth approximately $1,138,000. EAM Investors LLC acquired a new stake in shares of STRATA Skin Sciences during the 3rd quarter worth approximately $830,000. Renaissance Technologies LLC grew its holdings in shares of STRATA Skin Sciences by 164.6% during the 2nd quarter. Renaissance Technologies LLC now owns 293,499 shares of the medical device company’s stock worth $602,000 after purchasing an additional 182,579 shares in the last quarter. Finally, Macquarie Group Ltd. grew its holdings in shares of STRATA Skin Sciences by 89.7% during the 2nd quarter. Macquarie Group Ltd. now owns 134,033 shares of the medical device company’s stock worth $275,000 after purchasing an additional 63,393 shares in the last quarter. 27.48% of the stock is currently owned by hedge funds and other institutional investors.

SSKN opened at $2.86 on Wednesday. The company has a market capitalization of $80.55 million, a price-to-earnings ratio of 1.45 and a beta of 0.82. The company has a current ratio of 4.77, a quick ratio of 4.20 and a debt-to-equity ratio of 0.22. STRATA Skin Sciences has a 12-month low of $1.06 and a 12-month high of $3.88.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

Featured Story: How to Invest in Marijuana Stocks

Get a free copy of the Zacks research report on STRATA Skin Sciences (SSKN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply